We have previously shown that the selection of haplotype tag single nucleotide polymorphisms (htSNPs) and their statistical analysis in a multi-locus transmission/disequilibrium test (TDT) results in a more cost-effective genotyping strategy in disease association studies of genes by minimising redundancy due to linkage disequilibrium between SNPs. Further savings can be achieved by the use of a two-stage genotyping strategy. This approach is illustrated here in conjunction with the multi-locus TDT in determining whether common alleles of the immune regulatory genes RANK and its ligand TRANCE (RANKL) are associated with type 1 diabetes (T1D). A saving of approximately 75% of potential genotyping reactions could be made with minimal loss of power. There was little evidence from our analysis for association between the TRANCE and RANK genes and T1D in the populations tested.
Studies of genetic association between common variants, such as single nucleotide polymorphisms (SNPs), and common disease can often lack statistical power. The power of such studies depends on the number of families (or cases and controls) sampled and the number of the markers genotyped and their allele frequencies. 1 The continuing high cost of genotyping necessitates compromise between the sample size and the number of markers genotyped, and most reported associations have not been consistently reproduced. 2 Within small genomic regions in European populations, haplotype diversity is often limited and typing all known polymorphisms may lead to considerable redundancy. 3 Previously, we showed that haplotype diversity within regions of interest can be captured by a much smaller subset of markers, which we termed 'haplotype tag SNPs' (htSNPs). 3 We argued that genotyping htSNPs could potentially capture most of the information for association between disease and one or more common causal variants, and that the money saved in genotyping only htSNPs could be used to increase the number of patients sampled or the number of genes studied. In a recent survey of 17 genes and regions for which there are a priori grounds to suspect association with type 1 diabetes (T1D) [MIM 222100], we showed that the use of htSNPs reduced genotyping by approximately twothirds. 4 Here, we demonstrate that further savings in genotyping can be achieved with little loss in power, by use of a two-stage strategy incorporating 'stopping for futility'; that is, the second half of the sample is only genotyped if results from the first half offer some possibility of a significant overall result. There is an extensive literature on staged designs. 5, 6 Here though, we apply such designs to association studies using htSNPs and a multi-locus test, which tests the significance of the region.
Although a number of optimal methods for choosing htSNPs have been suggested, 3, 4, [7] [8] [9] less attention has been given to the problems of how such studies should be designed and analysed. Recently, we proposed a 'multilocus TDT' to test for association between disease and htSNPs due to linkage disequilibrium (LD) with one or more causal variants. 4 For each parent, we calculate a vector whose elements describe transmission of each of the htSNPs. If the parent is homozygous at a locus, the corresponding element is scored as zero, otherwise it is scored as either þ 1 or À1 depending on which allele was transmitted. The multi-locus TDT tests the mean of this vector against zero; it is asymptotically distributed as a w 2 with degrees of freedom (df) equal to the number of htSNPs. For case-control data, we score each diallelic locus as 0, 1 or 2 and compare mean score vectors between cases and controls. 4 This multi-locus test is essentially Hotelling's T 2 . 10 12 Graves' disease 13 and rheumatoid arthritis 14, 15 has been reported previously. Therefore, as well as being a functional candidate for T1D, RANK is also a positional candidate.
First, the two genes were resequenced in 96 individuals to identify and obtain genotypes for as many polymorphisms as possible in these two genes. These results provided estimates of common haplotype frequencies, thereby allowing optimal choice of htSNPs for our main association study. PCR products containing the exons and 3 kb of sequence 5 0 and 3 0 of the genes were sequenced in both directions in 96 individuals (48 parents of T1D and 48 unaffected controls) using ABI BigDye Terminator v2 chemistry and an ABI3700 DNA Analyser. In TRANCE, we sequenced all five exons. However, of the 10 exons in RANK, we were unable to adequately sequence exon 4 and 700 bases of exon 10, and, therefore, these regions were not included in the analysis. Sequence data were analysed using the Staden package. In all, 26 variants were identified from the sequencing of TRANCE, comprising 22 SNPs and four insertion/deletions (Indels); for this analysis Indels can be treated as biallelic SNPs. One rare SNP, DIL1239 (frequency 1.1%), in exon 5 produced a coding change of alanine to threonine. The sequencing of RANK identified 22 SNPs, five of which occurred in exons. Of these five exonic SNPs, only two produced coding changes. DIL1215 (frequency 48.8%) produced an alanine to valine change and DIL1218 (frequency 0.6%) produced a serine to glycine change. All SNP sequences and dbSNP ss/rs numbers are available at http://dil-gbrowse.cimr.cam. ac.uk/cgi-bin/DIL_GenomeView.cgi.
In order to minimise genotyping, we wish to type the smallest set of markers capable of predicting the causal variant. As the causal variant is unknown, we assume that the problem of predicting the causal variant is likely to be no more difficult than that of predicting any other marker. We use the resequencing data to investigate the ability of smaller subsets of markers to predict the genotypes of the remainder. Predictive performance was assessed using a locus R 2 measure, which measures the ability to predict each known marker by multiple regression on the htSNPs. 4 The use of a locus R 2 measure is dictated by arguments concerning the power of tests for association based on LD between htSNPs and a causal variant. 4, 16 We only considered SNPs with minor allele frequencies X3% and required the best subset of htSNPs to predict the remaining SNPs with minimum locus R 2 of 0.8. We selected optimal sets of htSNPs using a mixture of step-up, step-down and exhaustive subset search algorithms. Since exhaustive subset search can be slow, we first identified a set of htSNPs selected by both step-up and step-down searches, and determined the best additional set of htSNPs by exhaustive subset search of the remaining SNPs. Twelve TRANCE and eight RANK SNPs had minor allele frequencies below 3%. The optimal set of TRANCE and RANK htSNPs consisted of four (DIL1227, DIL1234, DIL1241 and DIL1247) and six (DIL1215, DIL1216, DIL1217, DIL1219, DIL1223 and DIL3817) SNPs. Tables 1 and 2 show the predictive performance of these htSNPs for the untyped SNPs in the 96 individuals sequenced.
The subsequent strategy was to genotype the htSNPs using Taqman (AB) in an initial set of 374 UK and 268 USA multiplex T1D families providing 1303 parent-child Cost-effective analysis of candidate genes using htSNPs CE Lowe et al trios (set 1) and to test for association using the multilocus TDT. We only proceeded to type htSNPs in the remaining 926 Finnish, 330 UK, 233 Romanian and 159 Norwegian (set 2), mostly simplex T1D families (set 2 includes 17 UK multiplex T1D families) providing 1668 trios, if the multi-locus test P-value for set 1 was less than or equal to 0.1. Most genes showing Po0.1 will not be associated with disease, but setting this threshold Pvalue relatively high is necessary in order to avoid rejecting true positives at the first stage. The relative size of sets 1 and 2 was necessarily determined by the availability of DNA. Set 1 (44% of available trios) consisted of families whose DNA is maintained as cell lines, which provide a plentiful supply of DNA, whereas set 2 consisted of families with a finite supply of DNA. After genotyping set 2, the analysis is performed on the entire data set (sets 1 and 2 combined). However, the Pvalue for this combined test must be corrected for the possibility of stopping for futility at the first stage ( Table 3 ). Note that, since a positive result must survive two statistical tests, the P-value is reduced by such a correction (see Appendix A for details); small nominal Pvalues require only small corrections, but large P-values are more seriously affected. Table 4 shows the power of this two-stage approach compared with the alternative single-stage strategy for various choices of causal allele frequency and the corresponding relative risk. The required (adjusted) P-value is taken as 0.0001, which we believe to be a justifiable choice for a candidate. There is little loss of power as a result of the use of a two-stage strategy. This is attributable to the low false-negative rate at stage 1 for effects for which the study, overall, is powered to detect. Table 5 shows the multi-locus test for TRANCE and single-locus tests for TRANCE htSNPs. No association between T1D and TRANCE was observed in set 1 (multilocus test P ¼ 0.274) and, consequently, the htSNPs were not genotyped in set 2.
The multi-locus test for RANK and single-locus tests for RANK htSNPs are shown in Table 6 . In set 1, the multi-locus test P-value for association between T1D and RANK was 0.104, as the P-value was only just above our threshold of 0.1, we genotyped the six htSNPs in set 2. Little evidence of association between T1D and RANK was observed in sets 1 and 2 combined (multi-locus test P ¼ 0.461; after correction for two-stage procedure P ¼ 0.080).
The htSNP approach reduced genotyping of common markers by about 71% and 57% for TRANCE and RANK, respectively. In addition, the two-stage design reduced genotyping by a further 66% for TRANCE as it did not proceed to set 2. Overall, the number of genotyping reactions performed at TRANCE was, therefore, reduced by about 90%, compared to the number that would have been performed had all the common markers been genotyped in both sets.
The htSNP approach and two-stage design have allowed us to investigate the common disease-common variant hypothesis in a more cost-effective manner. If the samples and funding are available more stages can be considered. Of course, it remains possible that there exists a common disease variant in either gene, which either has an effect smaller than would be detected with this study size or is in much weaker LD with the htSNPs than any other marker known to us. However, we would have been little better able to detect such a variant had we genotyped all markers in both sets. Indeed, the additional df and/or multiple testing corrections could have led to less statistical power. The programs for the selection of htSNPs and associations analysis used in this paper are implemented in the Stata statistical system, 18 and may be downloaded from www-gene.cimr.cam.ac.uk/clayton/soft ware. These programs include a multi-locus test for htSNPs genotyped in cases and controls, not used in this paper. We have also made available from this website the R programs 19 for power estimations and P-value adjustment, which can be used with family or case-control data. Minor allele frequency in 96 unrelated individuals. Ratio ¼ transmitted (T)/not transmitted (NT). The single-locus P-values were obtained using paired t-tests. The P-values allow for the nonindependence of transmissions within nuclear families, 17 since the region of Chr 18q22 containing RANK has previously shown some evidence of linkage to T1D.
14 Underlined SNP base is the transmitted allele.
